Extracorporeal Liver Support and Liver Transplant for Patients with Acute-on-Chronic Liver Failure

Han Li, Harvey Shi Hsien Chen, Scott Nyberg

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Recognition of acute-on-chronic liver failure (ACLF) as a unique entity is slowly evolving, as are therapies to improve survival of affected patients. Further investigation into its disease process and proper treatments with critical timing are important for improving patient survival. At this time, liver transplant is the only treatment known to improve survival in liver-failure patients. However, liver transplantation has its own disadvantages, such as organ shortage and the need for lifelong immunotherapy. Bridging therapies such as extracorporeal liver-support systems are attractive options to stabilize patients until transplantation or spontaneous recovery. The goals of these liver-support systems are to remove detoxification products, reduce systemic inflammation, and enhance regeneration of the injured liver. These devices have been under development for the past decade; a few are in clinical trials. At this time, there is no proven clearcut survival benefit in these devices, but they may improve the outcome of challenging cases and potentially avoid or postpone liver transplantation in some cases.

Original languageEnglish (US)
Pages (from-to)153-160
Number of pages8
JournalSeminars in Liver Disease
Volume36
Issue number2
DOIs
StatePublished - May 1 2016

Fingerprint

Transplants
Survival
Liver
Liver Transplantation
Equipment and Supplies
Liver Regeneration
Liver Failure
Therapeutics
Immunotherapy
Transplantation
Clinical Trials
Inflammation
Acute-On-Chronic Liver Failure

Keywords

  • acute-on-chronic liver failure
  • artificial liver-support systems
  • bioartificial liver-support systems
  • liver transplant

ASJC Scopus subject areas

  • Hepatology

Cite this

Extracorporeal Liver Support and Liver Transplant for Patients with Acute-on-Chronic Liver Failure. / Li, Han; Chen, Harvey Shi Hsien; Nyberg, Scott.

In: Seminars in Liver Disease, Vol. 36, No. 2, 01.05.2016, p. 153-160.

Research output: Contribution to journalArticle

@article{b5f03c00ac6a49ad9f4e761bf250d1b2,
title = "Extracorporeal Liver Support and Liver Transplant for Patients with Acute-on-Chronic Liver Failure",
abstract = "Recognition of acute-on-chronic liver failure (ACLF) as a unique entity is slowly evolving, as are therapies to improve survival of affected patients. Further investigation into its disease process and proper treatments with critical timing are important for improving patient survival. At this time, liver transplant is the only treatment known to improve survival in liver-failure patients. However, liver transplantation has its own disadvantages, such as organ shortage and the need for lifelong immunotherapy. Bridging therapies such as extracorporeal liver-support systems are attractive options to stabilize patients until transplantation or spontaneous recovery. The goals of these liver-support systems are to remove detoxification products, reduce systemic inflammation, and enhance regeneration of the injured liver. These devices have been under development for the past decade; a few are in clinical trials. At this time, there is no proven clearcut survival benefit in these devices, but they may improve the outcome of challenging cases and potentially avoid or postpone liver transplantation in some cases.",
keywords = "acute-on-chronic liver failure, artificial liver-support systems, bioartificial liver-support systems, liver transplant",
author = "Han Li and Chen, {Harvey Shi Hsien} and Scott Nyberg",
year = "2016",
month = "5",
day = "1",
doi = "10.1055/s-0036-1583197",
language = "English (US)",
volume = "36",
pages = "153--160",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "2",

}

TY - JOUR

T1 - Extracorporeal Liver Support and Liver Transplant for Patients with Acute-on-Chronic Liver Failure

AU - Li, Han

AU - Chen, Harvey Shi Hsien

AU - Nyberg, Scott

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Recognition of acute-on-chronic liver failure (ACLF) as a unique entity is slowly evolving, as are therapies to improve survival of affected patients. Further investigation into its disease process and proper treatments with critical timing are important for improving patient survival. At this time, liver transplant is the only treatment known to improve survival in liver-failure patients. However, liver transplantation has its own disadvantages, such as organ shortage and the need for lifelong immunotherapy. Bridging therapies such as extracorporeal liver-support systems are attractive options to stabilize patients until transplantation or spontaneous recovery. The goals of these liver-support systems are to remove detoxification products, reduce systemic inflammation, and enhance regeneration of the injured liver. These devices have been under development for the past decade; a few are in clinical trials. At this time, there is no proven clearcut survival benefit in these devices, but they may improve the outcome of challenging cases and potentially avoid or postpone liver transplantation in some cases.

AB - Recognition of acute-on-chronic liver failure (ACLF) as a unique entity is slowly evolving, as are therapies to improve survival of affected patients. Further investigation into its disease process and proper treatments with critical timing are important for improving patient survival. At this time, liver transplant is the only treatment known to improve survival in liver-failure patients. However, liver transplantation has its own disadvantages, such as organ shortage and the need for lifelong immunotherapy. Bridging therapies such as extracorporeal liver-support systems are attractive options to stabilize patients until transplantation or spontaneous recovery. The goals of these liver-support systems are to remove detoxification products, reduce systemic inflammation, and enhance regeneration of the injured liver. These devices have been under development for the past decade; a few are in clinical trials. At this time, there is no proven clearcut survival benefit in these devices, but they may improve the outcome of challenging cases and potentially avoid or postpone liver transplantation in some cases.

KW - acute-on-chronic liver failure

KW - artificial liver-support systems

KW - bioartificial liver-support systems

KW - liver transplant

UR - http://www.scopus.com/inward/record.url?scp=84966727955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966727955&partnerID=8YFLogxK

U2 - 10.1055/s-0036-1583197

DO - 10.1055/s-0036-1583197

M3 - Article

C2 - 27172357

AN - SCOPUS:84966727955

VL - 36

SP - 153

EP - 160

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 2

ER -